Immutep Expands US Patents for Efti Combination Therapies
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Immutep Ltd has announced the expansion of its United States patent estate for Efti-based combination therapies, with a new patent granted by the USPTO. This new patent adds to the existing portfolio, which now includes five patents related to combined preparations for cancer treatment. CEO Marc Voigt emphasized the importance of this patent for future development and partnership opportunities.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Immutep
- EFTISARC-NEO Survival Data reported in CTOS 2026 Abstract
- IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses
- IMP761 Late-Breaking Abstract at ACR shows T-Cell Inhibition
- Upcoming Poster Presentations at CTOS and ESMO IO 2026
- Immutep Quarterly Activities Report and Appendix 4C
Later from Immutep
All Immutep news releasesFollow Immutep into a list and get an email when it puts out news.
Follow Immutep